Listas | Seção | Observação |
---|---|---|
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | Sem observações |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Outras observações: Therapeutic alternatives: - 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain) (for lisinopril) - 4th level ATC chemical subgroup (C08CA Dihydropyridine derivatives) (for amlodipine) |
Listas | Seção | Observação |
---|---|---|
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | Sem observações |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Outras observações: Therapeutic alternatives: - 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain) (for lisinopril) - 4th level ATC chemical subgroup (C08CA Dihydropyridine derivatives) (for amlodipine) |
Listas | Seção | Observação |
---|---|---|
PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines | Sem observações |
WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Outras observações: Therapeutic alternatives: - 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain) (for lisinopril) - 4th level ATC chemical subgroup (C08CA Dihydropyridine derivatives) (for amlodipine) |